Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration ’s Actions

Recently, the US Food and Drug Administration (FDA) approved selinexor for patients with multiple myeloma, overruling the final vote of the Oncology Drug Advisory Committee (ODAC). Several oncologists voiced criticism of this approval, citing marginal objective response rate, largely partial response, and considerable toxicity.1,2

Source: Mayo Clinic Proceedings - January 31, 2020 Category: Internal Medicine Authors: Alyson Haslam, Jennifer Gill, Vinay Prasad Tags: Letter to the editor Source Type: research